User login
Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.
Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.
Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).
Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.
Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104
Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.
Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.
Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).
Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.
Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104
Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.
Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.
Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).
Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.
Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104